Does elevated asymmetric dimethylarginine impair endothelial vasodilation?

Elevated asymmetric dimethylarginine (ADMA) is biologically linked to endothelial dysfunction through inhibition of nitric-oxide synthase, but its clinical meaning depends on vascular and metabolic context—particularly relevant in older adults.

Clinical and vascular evidence

• ADMA is an endogenous L-arginine analogue that competitively inhibits endothelial nitric oxide synthase (eNOS). Reduced eNOS activity decreases endothelial nitric oxide (NO) production; because NO is central to endothelium-dependent relaxation, this impairs vasodilation.
• Human vascular evidence is directionally consistent: higher ADMA concentrations have been associated with lower flow-mediated dilation (FMD), including in a population cohort after adjustment for major cardiovascular risk factors.
• Prospectively, individuals in the highest versus lowest ADMA categories had approximately 42% higher cardiovascular-disease risk. This supports ADMA as a cardiovascular risk biomarker, not as an independently validated therapeutic target.

Mechanistic and clinical context

• The causal pathway is well established: ADMA → competitive eNOS inhibition → lower NO bioavailability → impaired endothelial vasodilation.
• The magnitude of direct inhibition at measured plasma concentrations is not uniform. The L-arginine/ADMA balance, oxidative stress, renal function, and underlying vascular disease can materially modify NO signaling and vascular effects.
• In older populations, associations are less consistent: in one elderly sample, ADMA was not independently associated with acetylcholine-mediated resistance-vessel dilation after multivariable adjustment. Age-related impairment in FMD also was not clearly attributable to higher ADMA or reversed by acute L-arginine.

Bottom line

• The claim is supported by strong mechanistic and human vascular evidence. For a 71-year-old man, an elevated ADMA level should be interpreted as a context-dependent marker of endothelial and cardiovascular risk, rather than a stand-alone diagnosis of endothelial dysfunction or a proven target for treatment.